Episode 127 - Ann Belien - Founder and CEO Rejuvenate Biomed

Ann is the Founder and CEO of Rejuvenate Biomed, a clinical-stage biotechnology company developing combination therapies aimed at targeting the biological mechanisms behind age-related diseases. With more than two decades of experience in pharmaceutical research and development, she has built a career focused on translating cutting-edge science into therapies that can improve patients’ lives.

Before launching Rejuvenate Biomed in 2017, Ann held leadership roles at Janssen Pharmaceuticals, part of Johnson & Johnson, where she worked across drug discovery, development, and innovation strategy. Her work has spanned multiple therapeutic areas including oncology, neurology, immunology, and infectious diseases.

Ann earned her PhD in neuro-oncology from the University of Zurich and conducted postdoctoral research at ETH Zurich, building a strong scientific foundation that she later brought into the biotech industry.